Biomica

Evogene Ltd. (NASDAQ: EVGN) (TASE:EVGN) released its financial results for the first quarter period ending March 31, 2023, revealing revenues of $641,000, an increase of 170% compared to $237,000 in the same period the previous year. The revenue increase was primarily due to revenues recognized per...

Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN) Q2 2022 revenue was $312,000, an increase of 131% compared to $135,000 in the same period the previous year. Revenues were primarily due to the initial sales of Lavie Bio's Thrivus product (previously branded as Result) and sales of Canonic products in...

Computational biology company Evogene Ltd. (NASDAQ: EVGN)  will release its financial results for the full year and fourth quarter of 2021 on March 10, 2022. On the day of the announcement, the company's management will host a conference call to discuss the results at 09:00 a.m. EST....